After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Gilead Sciences has put $66 million down to start a collaboration with San Diego start-up Tentarix Biotherapeutics to develop new therapeutics for cancer and inflammatory diseases. The agreement ...

In the latest market close, Gilead Sciences (GILD) reached $85.21, with a +0.92% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Meanwhile, ...

Gilead Sciences is wasting no time in promoting worldwide ... the generics companies can make and sell lenacapavir under its current indication—to treat heavily treatment-experienced adults ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In response to increased criticism of its pricing, Gilead Sciences has reached voluntary licensing deals with companies to make generic versions of its twice-yearly HIV medicine, lenacapavir ...

Gilead Sciences (GILD – Research Report) received a Buy rating and price target from Wells Fargo analyst Mohit Bansal today. The ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

In the latest market close, Gilead Sciences (GILD) reached $85.21 ... For the full year, the Zacks Consensus Estimates project earnings of $3.78 per share and a revenue of $27.63 billion ...

**NM signifies a non meaningful value. A dash signifies the data is not available.